Key Drivers
- Strong margins
- Solid cash flow
- Rising leverage
AIAI Summary
QGEN now looks more like a cash-generative, product-execution story than a pure growth re-rating, with strong margins and free cash flow supporting the dividend and new product rollouts, but the stock likely stays range-bound unless QIAcuity/QIAstat-Dx adoption lifts the growth floor and U.S. instrument demand stabilizes.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid cash flow
- •Rising leverage
QGEN shows strong profitability and cash generation with improving margins and ample liquidity, but rising leverage, shrinking equity, and a high-intangible asset base temper the otherwise solid outlook.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout attempt
- •Support holding
Over the last month, QGEN has made a modest gain with higher lows and a breakout to $43.85, but the pullback to $42.95 leaves the trend constructive rather than decisive above $41.40-$41.70 support.
New high at $43.85 was followed by a quick pullback to $42.95, showing cooling momentum
Sentiment & News
Key News Insights:
- •Q2 Beat
- •FDA Clearance
- •Revenue Mix
Qiagen delivered a Q2 beat with sales and EPS ahead of expectations while also gaining U.S. FDA clearance for its first QIAstat-Dx bloodstream infection panel, reinforcing its diagnostics growth story.
The strong earnings surprise and expanded U.S. test menu are likely to support QGEN sentiment, though international revenue concentration remains a key risk to monitor
Similar Companies in Healthcare
Other companies in the same sector with AI ratings